Expert Point of View: Jason Aboudi Mouabbi, MD
“These results [from the TRIO-US B-12 TALENT trial] are exciting and impressive in HER2-low, hormone receptor–positive patients. The authors were testing the waters and got a positive signal,” said Jason Aboudi Mouabbi, MD, a medical oncologist at MD Anderson Cancer Center, Houston.
“The beauty of this is that hormone receptor–positive breast cancer does not respond well to neoadjuvant chemotherapy. Perhaps, we can use antibody-drug conjugates earlier in these patients to improve outcomes. However, it wasn’t compared with chemotherapy in this study,” he continued. “The single arm [of T-DXd (fam-trastuzumab deruxtecan-nxki)] did well in this trial. I would be really excited to see T-DXd compared with chemotherapy in a head-to-head comparison.”
Dr. Mouabbi continued: “The authors reported a 15% clinical complete response in combination with residual cancer burden [RCB] 0/1, which is better than what is achieved with neoadjuvant chemotherapy. It is exciting and encouraging.”
“Other antibody-drug conjugates have different targets. I predict that the next decade in cancer treatment will be the decade of antibody-drug conjugates,” he added.
Regarding HER2-low cancer, Dr. Mouabbi said it is very difficult to distinguish between HER2 0 and HER2 1. “I have had patients who were originally classified as HER2 0, and upon recheck, they will almost always be labeled as HER2 1+ or HER2-low. The line is blurry. We want to be able to find the low expressors because we don’t want to deny patients this treatment,” he explained.
DISCLOSURE: Dr. Mouabbi has received honoraria from BostonGene, GE HealthCare, Cardinal Health, Napo Pharmaceuticals, and Fresenius Kabi.